NCT05806177View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Alzheimer Disease
Interventions
DRUG

AD16 30mg、40mg

AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study

DRUG

AD16 Placebo 30mg、40mg

AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study

Trial Locations (1)

Unknown

The Central South University Xiang Ya Hospital, Changsha

All Listed Sponsors
collaborator

Xiangya Hospital of Central South University

OTHER

lead

South China Center For Innovative Pharmaceuticals

OTHER

NCT05806177 - Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects | Biotech Hunter | Biotech Hunter